Beijing Biostar Pharmaceuticals Co., Ltd. (HKG:2563)

Market Cap	1.39B -87.0%
Revenue (ttm)	58.66M +63.1%
Net Income	-139.45M
EPS	-0.39
Shares Out	364.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,800
Average Volume	25,340
Open	3.790
Previous Close	3.850
Day's Range	3.790 - 3.840
52-Week Range	2.400 - 10.580
Beta	n/a
RSI	54.69
Earnings Date	Mar 25, 2026

About HKG:2563

Beijing Biostar Pharmaceuticals Co., Ltd., a synthetic biology-driven biopharmaceutical company, engages in the research, development, manufacture, and commercialization of oncology products in the People’s Republic of China. The company develops Utidelone injection, a microtubule inhibitor for the treatment of advanced and neoadjuvant breast cancer, advanced non-small cell lung cancer, gastric and esophageal cancer, brain metastasis, solid tumors, and glioblastoma. It is also involved in the development of Utidelone capsule that is in Phase II...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 131
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2563

Financial Performance

In 2024, HKG:2563's revenue was 71.87 million, an increase of 7.85% compared to the previous year's 66.64 million. Losses were -143.78 million, -24.19% less than in 2023.

Financial numbers in CNY